Sakar Healthcare opened lower at ₹971.10, compared with its previous close of ₹981.50. During today's session, the stock has traded between ₹914.10 and ₹982.70, with an average traded price of ₹940.77. It is currently showing a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Sakar Healthcare is now worth
₹ 53,266.00
giving a profit of
₹ 43,266.00 (432.66%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-29.90 (-3.05%)
Day High
₹982.70
Day Low
₹914.10
Day Open
₹971.10
Prev Close
₹981.50
Volume
2,45,153
Value Traded
₹23.06 Cr
1W Return
-5.48%
1M Return
-17.86%
3M Return
15.42%
6M Return
61.44%
1Y Return
165.48%
Market Cap (₹ Cr.)
2,117
PE Ratio
60.50
PB Ratio
6.73
Dividend Yield
-
ROE
9.40%
ROCE
12.82%
Book Value (₹)
145.82
Face Value (₹)
10.00
EPS (TTM)
4.62
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-5.48%
6 Week
-
1 Month
-17.86%
3 Month
15.42%
9 Month
154.57%
Sakar Healthcare eyes ₹200 crore oncology revenue in FY27
Sakar Healthcare delivered strong Q1FY27 results with PAT surging 120% to ₹1,028.49 lakhs. During the earnings call, management outlined plans to double oncology revenue to ₹200 crore in FY27, leveraging 16 marketing authorizations and API backward integration to potentially lift EBITDA margins to 35%.
2mo agoCobra India acquires 2.05% stake in Sakar Healthcare via open market
Cobra India (Mauritius) Limited disclosed the acquisition of 489,026 shares in Sakar Healthcare Limited, increasing its holding. The transaction, executed via open market operations on June 11, 2026, represents 2.0462% of the target company's total paid-up equity share capital.
3mo agoSakar Healthcare FY26 net profit rises 74% to ₹3048.46 lakh
Sakar Healthcare reported a 74% increase in net profit to ₹3048.46 lakh for FY26, with revenue rising to ₹25173.60 lakh. The Board approved the audited results and appointed a new secretarial auditor.
4mo agoSakar Q4 Profit Surges 91% on Oncology Growth
Sakar Healthcare reported a 91% YoY surge in Q4 net profit to INR1,102.43 lakhs, driven by a 42% rise in revenue and strong oncology segment performance. The company also disclosed the transcript of its May 15, 2026 earnings call.
4mo agoSakar signs 40th oncology deal with Zydus for GCC markets
Sakar Healthcare has signed its 40th agreement with Zydus Lifesciences for oncology products in GCC and emerging markets. The company reported progress in the European Union with 23 Marketing Authorization filings and 5 site variation approvals. Additionally, Sakar has developed 21 APIs in-house, including 16 with Written Confirmation and 2 CEP approvals.
4mo agoSakar Healthcare's Secretarial Auditor M/s. Nishant Pandya & Associates Resigns with Immediate Effect
Sakar Healthcare Limited disclosed the resignation of its Secretarial Auditors, M/s. Nishant Pandya & Associates (ACS-51005, COP No. 22435), with immediate effect from Financial Year 2025-26 onwards. The resignation, dated 6th May, 2026, was attributed to personal reasons, with the firm confirming no other material reasons. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was submitted by Company Secretary Bharat Soni.
5mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 5 years ago in Sakar Healthcare is now worth
₹ 53,266.00
giving a profit of
₹ 43,266.00 (432.66%)
Note: Past profits do not guarantee future returns.
